The response rate for ketamine therapy in treatment-resistant depression is approximately 50 to 70 percent after a single intravenous infusion, as measured at the 24-hour mark. Remission rates -- meaning near-complete resolution of depressive symptoms -- are approximately 30 percent after a single treatment. These figures are particularly significant because ketamine patients have typically already failed two or more conventional antidepressants.
How Are Response Rates Measured?
In ketamine research, "response" is defined as a 50% or greater reduction in depression severity scores on standardized instruments such as the Montgomery-Asberg Depression Rating Scale (MADRS) or the Hamilton Depression Rating Scale (HDRS). "Remission" indicates scores falling below the clinical threshold for depression. These are the same metrics used to evaluate all antidepressant treatments, allowing direct comparison.
By contrast, traditional antidepressants show response rates of approximately 30 to 40 percent in treatment-resistant populations after 6 to 8 weeks of use. Ketamine achieves comparable or superior response rates in hours rather than weeks, which is why it represents such a significant advance for patients with severe, refractory depression.
What Influences Response?
Several factors affect the likelihood of responding to ketamine therapy. A 2015 meta-analysis by Newport and colleagues found consistent response rates across studies, but individual variability remains significant. Patients with a family history of alcohol use disorder, those with higher baseline anxiety, and those with fewer prior medication failures may respond at higher rates, though these predictors are not definitive.
Repeated infusion protocols -- typically a series of 6 infusions over 2 to 3 weeks -- generally produce higher cumulative response rates than single infusions. Some patients who do not respond to the first infusion will respond after the second or third treatment. Dose adjustments may also improve outcomes for initial non-responders.
Concurrent medications can influence response rates as well. Some evidence suggests that benzodiazepine use may reduce ketamine's antidepressant efficacy, while lamotrigine may modulate its side effect profile without clearly diminishing its therapeutic benefit.
For a deeper exploration of ketamine's evidence base in depression, see the Ketamine for Depression Comprehensive Guide.
References
- PubMed: Efficacy of Intravenous Ketamine for Treatment-Resistant Depression: A Systematic Review and Meta-Analysis — Meta-analysis documenting ketamine response and remission rates across trials
- NIMH: Depression Overview — National Institute of Mental Health overview of depression research and treatment
- PubMed: Ketamine for Treatment-Resistant Depression: Recent Developments and Clinical Considerations — Review of response predictors and clinical outcome measures
Share